JO2852B1 - Anti-cancer compounds and pharmaceutical compositions - Google Patents

Anti-cancer compounds and pharmaceutical compositions

Info

Publication number
JO2852B1
JO2852B1 JO2010163A JOP20100163A JO2852B1 JO 2852 B1 JO2852 B1 JO 2852B1 JO 2010163 A JO2010163 A JO 2010163A JO P20100163 A JOP20100163 A JO P20100163A JO 2852 B1 JO2852 B1 JO 2852B1
Authority
JO
Jordan
Prior art keywords
compound
pharmaceutical composition
cancer compound
acid
cancer
Prior art date
Application number
JO2010163A
Other languages
Arabic (ar)
English (en)
Inventor
جين-كريستوف كاري
ميشيل تشيف
فرانكويس كليرك
سيسيل كومبيا
سيلفي جونتير
الاين كريك
سيلفيتي لاتشايد
لورانت سشيو
Original Assignee
سانوفي - أفينتس
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سانوفي - أفينتس filed Critical سانوفي - أفينتس
Application granted granted Critical
Publication of JO2852B1 publication Critical patent/JO2852B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
JO2010163A 2009-05-18 2010-05-16 Anti-cancer compounds and pharmaceutical compositions JO2852B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0902392A FR2945535B1 (fr) 2009-05-18 2009-05-18 Compose anticancereux et composition pharmaceutique le contenant

Publications (1)

Publication Number Publication Date
JO2852B1 true JO2852B1 (en) 2015-03-15

Family

ID=40973187

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2010163A JO2852B1 (en) 2009-05-18 2010-05-16 Anti-cancer compounds and pharmaceutical compositions

Country Status (35)

Country Link
US (2) US9073917B2 (es)
EP (1) EP2432766B1 (es)
JP (1) JP5656981B2 (es)
KR (1) KR20120032483A (es)
CN (1) CN102459193B (es)
AR (1) AR076686A1 (es)
AU (1) AU2010251013B2 (es)
BR (1) BRPI1012201A2 (es)
CA (1) CA2762233C (es)
CL (1) CL2011002930A1 (es)
CO (1) CO6400138A2 (es)
CY (1) CY1114850T1 (es)
DK (1) DK2432766T3 (es)
EA (1) EA021084B1 (es)
ES (1) ES2430989T3 (es)
FR (1) FR2945535B1 (es)
HK (1) HK1167388A1 (es)
HR (1) HRP20130959T1 (es)
IL (1) IL216361A0 (es)
JO (1) JO2852B1 (es)
MA (1) MA33356B1 (es)
ME (1) ME01542B (es)
MX (1) MX2011012356A (es)
MY (1) MY152995A (es)
NZ (1) NZ596464A (es)
PL (1) PL2432766T3 (es)
PT (1) PT2432766E (es)
RS (1) RS53002B (es)
SG (1) SG176169A1 (es)
SI (1) SI2432766T1 (es)
SM (1) SMT201400005B (es)
TW (1) TWI441822B (es)
UY (1) UY32644A (es)
WO (1) WO2010133794A1 (es)
ZA (1) ZA201108447B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
ES2719776T3 (es) 2012-10-12 2019-07-16 Broad Inst Inc Inhibidores de GSK3 y métodos de uso de los mismos
WO2016002968A1 (en) 2014-07-01 2016-01-07 Takeda Pharmaceutical Company Limited Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
BR112019020810A2 (pt) 2017-04-05 2020-04-28 Biogen Ma Inc compostos tricíclicos como inibidores de glicogênio sintase cinase 3 (gsk3) e usos dos mesmos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036422A1 (en) 1999-11-19 2001-05-25 Abbott Laboratories Tricyclic dihydropyrimidine potassium channel openers
CN1630656A (zh) 2001-02-02 2005-06-22 三菱制药株式会社 二氢吡唑并吡啶化合物及其制药用途
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
CA2528938A1 (en) 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
RS51351B (en) 2005-07-20 2011-02-28 Aventis Pharma S.A. 1,4-DIHYDROPYRIDINE-CONDENSED HTEROCYCLES, PROCEDURES FOR THEIR PRODUCTION, USE AND THE COMPOSITIONS CONTAINING THEM
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant

Also Published As

Publication number Publication date
JP2012527436A (ja) 2012-11-08
NZ596464A (en) 2014-01-31
US9221817B2 (en) 2015-12-29
TW201100418A (en) 2011-01-01
AU2010251013B2 (en) 2015-08-20
CN102459193A (zh) 2012-05-16
HK1167388A1 (en) 2012-11-30
CO6400138A2 (es) 2012-03-15
DK2432766T3 (da) 2013-10-28
EP2432766A1 (fr) 2012-03-28
ZA201108447B (en) 2013-01-30
US9073917B2 (en) 2015-07-07
ES2430989T3 (es) 2013-11-22
CY1114850T1 (el) 2016-12-14
CL2011002930A1 (es) 2012-06-29
JP5656981B2 (ja) 2015-01-21
CN102459193B (zh) 2014-08-27
SI2432766T1 (sl) 2013-11-29
RS53002B (en) 2014-04-30
CA2762233C (fr) 2017-11-28
AR076686A1 (es) 2011-06-29
SMT201400005B (it) 2014-03-07
FR2945535A1 (fr) 2010-11-19
CA2762233A1 (fr) 2010-11-25
US20120220621A1 (en) 2012-08-30
SG176169A1 (en) 2011-12-29
PT2432766E (pt) 2013-10-23
IL216361A0 (en) 2012-01-31
HRP20130959T1 (hr) 2013-11-22
MA33356B1 (fr) 2012-06-01
KR20120032483A (ko) 2012-04-05
EA021084B1 (ru) 2015-04-30
TWI441822B (zh) 2014-06-21
EA201171429A1 (ru) 2012-05-30
BRPI1012201A2 (pt) 2016-04-05
FR2945535B1 (fr) 2011-06-10
ME01542B (me) 2014-04-20
US20150266877A1 (en) 2015-09-24
EP2432766B1 (fr) 2013-07-17
MX2011012356A (es) 2011-12-14
WO2010133794A1 (fr) 2010-11-25
UY32644A (es) 2010-12-31
AU2010251013A1 (en) 2011-12-08
MY152995A (en) 2014-12-31
PL2432766T3 (pl) 2013-12-31

Similar Documents

Publication Publication Date Title
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
UA94052C2 (uk) Похідні піридазину
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
GEP20125459B (en) Compounds for inhibiting mitotic progression
UA105229C2 (uk) Фармацевтичний склад
HRP20080493T3 (en) Substituted quinoline derivatives as mitotic kinesin inhibitors
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2006077025A3 (en) Morpholines as 5ht2c agonists
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
MX2010005824A (es) Derivados de aminotiazol.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
MX2009007260A (es) Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
WO2012035480A3 (en) Pharmaceutical compositions of curcumin
JO2852B1 (en) Anti-cancer compounds and pharmaceutical compositions
MX2009003169A (es) Derivados de sulfonamida.
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
MX2009004295A (es) Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.
IL194094A0 (en) Stable pharmacuetical compositions of 2-aza-bicyclol[3.3.0]-octane-3-carboxylic acid derivatives
JO2820B1 (en) Combination of refined thiazolium salt or a primary compound and artemisinin or a derivative thereof to treat serious malaria cases
TW200635581A (en) Formulations of azetidine derivatives which can be injected or administered orally
TW200738703A (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
TR200802061A2 (tr) Yüksek oranda aktif madde içeren farmasötlk formülasyon.